Nabumetone tablets are for oral administration. They can be taken with or without food. Taking with food may help to reduce gastrointestinal upset.

Nabumetone is a prodrug that is rapidly metabolized in the liver to its active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA). 6-MNA inhibits cyclooxygenase (COX) enzymes, primarily COX-2, leading to reduced prostaglandin synthesis. Prostaglandins are mediators of inflammation, pain, and fever.

• •Known hypersensitivity to nabumetone or any component of the formulation, or to other NSAIDs.
• •History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
• •Peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
• •Severe heart failure.
• •Third trimester of pregnancy.

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Management involves symptomatic and supportive care. Gastric lavage and/or activated charcoal may be considered if ingestion is recent.

Pregnancy: Avoid in the third trimester due to risk of premature closure of the fetal ductus arteriosus. Use in early pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Nabumetone's active metabolite is excreted in breast milk in small amounts; use with caution in nursing mothers, or consider alternatives.